Vanguard Group’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,225,613
| Closed | -$193M | – | 4138 |
|
|
2019
Q4 | $193M | Buy |
3,225,613
+1,032,401
| +47% | +$38.7M | 0.01% | 1407 |
|
|
2019
Q3 | $61.6M | Buy |
2,193,212
+222,006
| +11% | +$7.58M | ﹤0.01% | 1972 |
|
|
2019
Q2 | $74.6M | Buy |
1,971,206
+84,659
| +4% | +$3.25M | ﹤0.01% | 1901 |
|
|
2019
Q1 | $73.6M | Buy |
1,886,547
+180,018
| +11% | +$5.16M | ﹤0.01% | 1888 |
|
|
2018
Q4 | $36.4M | Buy |
1,706,529
+363,598
| +27% | +$9.38M | ﹤0.01% | 2177 |
|
|
2018
Q3 | $53.2M | Buy |
1,342,931
+24,585
| +2% | +$916K | ﹤0.01% | 2110 |
|
|
2018
Q2 | $50.4M | Buy |
1,318,346
+144,040
| +12% | +$5.33M | ﹤0.01% | 2121 |
|
|
2018
Q1 | $35.3M | Buy |
1,174,306
+267,945
| +30% | +$9.07M | ﹤0.01% | 2249 |
|
|
2017
Q4 | $28.3M | Buy |
906,361
+153,115
| +20% | +$4.2M | ﹤0.01% | 2346 |
|
|
2017
Q3 | $21.1M | Buy |
753,246
+74,834
| +11% | +$1.63M | ﹤0.01% | 2465 |
|
|
2017
Q2 | $13M | Buy |
678,412
+383,837
| +130% | +$6.13M | ﹤0.01% | 2650 |
|
|
2017
Q1 | $5.02M | Buy |
294,575
+22,283
| +8% | +$360K | ﹤0.01% | 3050 |
|
|
2016
Q4 | $4.97M | Buy |
272,292
+32,231
| +13% | +$557K | ﹤0.01% | 3066 |
|
|
2016
Q3 | $4.28M | Buy |
+240,061
| New | +$3.64M | ﹤0.01% | 3084 |
|
Vanguard Group's BOLD Position: Q1 2020 in Review
Vanguard Group sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 3,225,613 shares — an estimated $193M sold.
Vanguard Group first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $193M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Vanguard Group reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Vanguard Group sold 3,225,613 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $193M.
- Vanguard Group first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Vanguard Group's Audentes Therapeutics, Inc position peaked at $193M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Vanguard Group's 13F filing for Q1 2020, filed 15 May 2020.